GSK reports third-quarter growth and declares 17 pence dividend per GSK stock

Published on 10/28/2026 at 10:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GSK reported GBP 8.89 billion in third-quarter sales, up 5 percent at constant currency. The company declared a 17 pence dividend per GSK stock.

Growth is concentrated in medicines

GSK reported GBP 8.89 billion in third-quarter sales on October 28, 2026.
Specialty Medicines sales rose 15 percent to GBP 3.9 billion in the third quarter.
GSK declared a 17 pence third interim dividend and reaffirmed 3 to 5 percent sales growth guidance.

GSK, GB00BN7SWP63, Illustration mit AI erstellt.

GSK reported GBP 8.89 billion in third-quarter sales on October 28, 2026, up 4 percent at actual exchange rates and 5 percent at constant exchange rates. The GSK release said Specialty Medicines drove the result, while the company reaffirmed its full-year outlook and declared a 17 pence third interim dividend.

Specialty medicines lead growth

Specialty Medicines sales increased 15 percent to GBP 3.9 billion in the third quarter. HIV sales rose 10 percent to GBP 2.1 billion, while Respiratory, Immunology and Inflammation sales advanced 21 percent to GBP 1.1 billion and Oncology sales climbed 23 percent to GBP 0.6 billion, according to the GSK results announcement.

The portfolio mix also exposed a pressure point. Vaccines sales fell 2 percent to GBP 2.6 billion, with Shingrix sales down 5 percent to GBP 0.8 billion and Arexvy sales down 24 percent to GBP 0.2 billion. General Medicines sales were stable at GBP 2.4 billion.

Why guidance matters for growth

Core operating profit rose 5 percent at constant exchange rates, while core earnings per share increased 1 percent. Reported operating profit fell 16 percent because of GBP 328 million in restructuring charges linked to the Accelerate Growth program, showing the difference between underlying momentum and reported earnings.

GSK reaffirmed 2026 guidance for sales growth of 3 to 5 percent, with the outcome expected in the upper half of the range. Core operating profit growth of 7 to 9 percent is also expected in the upper half, while core earnings per share growth of 7 to 9 percent is expected in the lower half, the company announcement said.

The next investor question

The central issue is whether specialty growth can continue to offset weaker vaccine demand while research spending and restructuring costs remain elevated. The declared dividend is 17 pence per share for the third quarter, and GSK expects total dividends for 2026 to reach 70 pence per share.

The further course of trading is shown by the continuously updated real-time quote of GSK stock.